Takeda CEO says Japanese drugmaker back on track

Takeda Pharmaceutical has its work cut out. On the heels of a big earnings shortfall, the Japanese drugmaker's CEO is touting its cost-cutting programs and growth in emerging markets. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.